AU2016358324B2 - Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy - Google Patents

Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy Download PDF

Info

Publication number
AU2016358324B2
AU2016358324B2 AU2016358324A AU2016358324A AU2016358324B2 AU 2016358324 B2 AU2016358324 B2 AU 2016358324B2 AU 2016358324 A AU2016358324 A AU 2016358324A AU 2016358324 A AU2016358324 A AU 2016358324A AU 2016358324 B2 AU2016358324 B2 AU 2016358324B2
Authority
AU
Australia
Prior art keywords
compound
peptide
cancer
conjugate
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016358324A
Other languages
English (en)
Other versions
AU2016358324A1 (en
Inventor
Borhane Annabi
Richard Beliveau
Cyndia CHARFI
Jean-Christophe Currie
Michel Demeule
Alain LAROCQUE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transfert Plus SC
Original Assignee
Transfert Plus SC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transfert Plus SC filed Critical Transfert Plus SC
Publication of AU2016358324A1 publication Critical patent/AU2016358324A1/en
Priority to AU2021201085A priority Critical patent/AU2021201085B2/en
Application granted granted Critical
Publication of AU2016358324B2 publication Critical patent/AU2016358324B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/083—Neurotensin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2016358324A 2015-11-24 2016-11-24 Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy Active AU2016358324B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021201085A AU2021201085B2 (en) 2015-11-24 2021-02-19 Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562259178P 2015-11-24 2015-11-24
US62/259,178 2015-11-24
PCT/CA2016/051379 WO2017088058A1 (en) 2015-11-24 2016-11-24 Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021201085A Division AU2021201085B2 (en) 2015-11-24 2021-02-19 Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy

Publications (2)

Publication Number Publication Date
AU2016358324A1 AU2016358324A1 (en) 2018-07-05
AU2016358324B2 true AU2016358324B2 (en) 2021-03-11

Family

ID=58762819

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016358324A Active AU2016358324B2 (en) 2015-11-24 2016-11-24 Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
AU2021201085A Active AU2021201085B2 (en) 2015-11-24 2021-02-19 Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021201085A Active AU2021201085B2 (en) 2015-11-24 2021-02-19 Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy

Country Status (13)

Country Link
US (4) US11034727B2 (OSRAM)
EP (2) EP3380495B1 (OSRAM)
JP (2) JP6810146B2 (OSRAM)
CN (2) CN108473541B (OSRAM)
AU (2) AU2016358324B2 (OSRAM)
CA (2) CA3006313C (OSRAM)
DK (1) DK3380495T3 (OSRAM)
ES (1) ES2882634T3 (OSRAM)
PL (1) PL3380495T3 (OSRAM)
PT (1) PT3380495T (OSRAM)
SI (1) SI3380495T1 (OSRAM)
WO (1) WO2017088058A1 (OSRAM)
ZA (1) ZA201804117B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2882634T3 (es) * 2015-11-24 2021-12-02 Transfert Plus Sec Compuestos peptídicos y conjugados con péptidos para el tratamiento del cáncer mediante quimioterapia mediada por receptores
JP2020527596A (ja) * 2017-05-24 2020-09-10 トランスファート プラス，エス．イー．シー． 炎症性疾患の治療のためのペプチド化合物、コンジュゲート化合物及びそれらの使用
US11389460B2 (en) 2017-09-15 2022-07-19 City Of Hope Methods and compositions for treating endometrial cancer
CN111819203A (zh) * 2018-03-01 2020-10-23 葛莱高托普有限公司 包含抗muc1抗体和il-15的融合蛋白构建体
WO2020037434A1 (en) * 2018-08-24 2020-02-27 Transfert Plus, S.E.C. Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry
WO2020254683A2 (en) * 2019-06-20 2020-12-24 Aarhus Universitet Sorcs2 crystal structure and uses thereof
JP2023505298A (ja) * 2019-12-06 2023-02-08 ゼラテクノロジーズ インコーポレイテッド がんを治療するためのソルチリン結合コンジュゲート化合物、組成物、およびそれらの使用
US20230338555A1 (en) * 2020-05-18 2023-10-26 Ionis Pharmaceuticals, Inc. Conjugated oligonucleotides and uses thereof
JP2024508847A (ja) * 2021-02-26 2024-02-28 トランスフェール プリュ ソシエテ アン コマンディット がん幹細胞を標的とするための方法及びソルチリン結合コンジュゲート化合物
CN116731113A (zh) * 2022-03-01 2023-09-12 上海智肽生物科技有限公司 针对sort1的多肽化合物及其药物偶联物
CN120641133A (zh) * 2022-11-14 2025-09-12 瑟瑞技术公司 用于刺激抗肿瘤免疫应答的药物缀合物化合物
WO2025054707A1 (en) * 2023-09-11 2025-03-20 Theratechnologies Inc. Peptide conjugates of camptothecin analogs and uses thereof
CN117904303B (zh) * 2024-03-18 2024-06-18 湖南宏雅基因技术有限公司 Sorcs1基因甲基化和pax1基因甲基化联合诊断的检测引物探针组在制备宫颈癌诊断产品中的应用
CN118384289A (zh) * 2024-04-24 2024-07-26 青岛科技大学 一种肿瘤靶向肽及多肽偶联药物的制备方法及应用
WO2025236098A1 (en) * 2024-05-16 2025-11-20 Theratechnologies Inc. Peptide conjugates of maytansinoids and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8344211B2 (en) * 2008-08-13 2013-01-01 Ceres, Inc. Plant nucleotide sequences and corresponding polypeptides

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
FI101678B (fi) 1990-12-31 1998-08-14 Akzo Nv Happolabiileja kytkentämolekyylejä
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand
WO2002046227A2 (en) 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
TW200634019A (en) 2004-12-21 2006-10-01 Wyeth Corp Thienoisoquinoline-phenylsulfonamides and their use as er-nfkb inhibitors
DK2687223T4 (da) 2006-05-30 2025-02-17 Mayo Found Medical Education & Res Påvisning og behandling af demens
EP2077278A1 (fr) * 2007-12-21 2009-07-08 Centre National de la Recherche Scientifique (CNRS) Peptide dérivé du récepteur 3 de la neurotensine et utilisation dans le traitemement de maladies psychiatriques
KR101614558B1 (ko) * 2008-04-27 2016-04-22 하. 룬드벡 아크티에셀스카브 인간 소르틸린의 결정 구조 및 소르틸린에 대한 리간드를 확인하기 위한 이의 용도
WO2010022175A1 (en) * 2008-08-19 2010-02-25 Yale University Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin
CN102307904A (zh) * 2008-12-05 2012-01-04 安吉奥开米公司 神经降压素或神经降压素类似物的缀合物及其用途
US8147849B2 (en) 2009-02-20 2012-04-03 Novartis Ag Protective antigens for group B Streptococcus hypervirulent strains
US9161988B2 (en) 2009-07-02 2015-10-20 Angiochem Inc. Multimeric peptide conjugates and uses thereof
WO2011082290A2 (en) 2009-12-31 2011-07-07 Organomed Corporation Formulations from natural products, turmeric, and aspirin
EP2740726A1 (en) * 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
MX393951B (es) 2015-04-07 2025-03-24 Alector Llc Anticuerpos antisortilina y métodos para su uso.
ES2882634T3 (es) 2015-11-24 2021-12-02 Transfert Plus Sec Compuestos peptídicos y conjugados con péptidos para el tratamiento del cáncer mediante quimioterapia mediada por receptores
JP2020527596A (ja) * 2017-05-24 2020-09-10 トランスファート プラス，エス．イー．シー． 炎症性疾患の治療のためのペプチド化合物、コンジュゲート化合物及びそれらの使用
WO2020037434A1 (en) * 2018-08-24 2020-02-27 Transfert Plus, S.E.C. Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8344211B2 (en) * 2008-08-13 2013-01-01 Ceres, Inc. Plant nucleotide sequences and corresponding polypeptides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Fatemeh Ghaemimanesh ET AL, "The effect of sortilin silencing on ovarian carcinoma cells", Avicenna journal of medical biotechnology, Iran, (2014-07-01), pages 169 - 177, URL: http://www.ajmb.org/PDF/En/FullText/182.pdf, (2019-01-14) *
OLGA SERUP ANDERSEN ET AL, "Identification of a Linear Epitope in Sortilin That Partakes in Pro-neurotrophin Binding", JOURNAL OF BIOLOGICAL CHEMISTRY (2010), vol. 285, no. 16, pages 12210 - 12222 *
SÉVERINE ROSELLI ET AL, "Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion", ONCOTARGET, (2015-04-30), vol. 6, no. 12, doi:10.18632/oncotarget.3401 *

Also Published As

Publication number Publication date
ES2882634T3 (es) 2021-12-02
CA3006313A1 (en) 2017-06-01
PT3380495T (pt) 2021-08-19
EP3380495B1 (en) 2021-05-19
EP3925969C0 (en) 2025-09-03
SI3380495T1 (sl) 2022-01-31
EP3380495A1 (en) 2018-10-03
CN108473541B (zh) 2023-05-12
US20200392184A1 (en) 2020-12-17
JP2019501141A (ja) 2019-01-17
EP3380495A4 (en) 2019-02-27
JP2020189867A (ja) 2020-11-26
US12269902B2 (en) 2025-04-08
EP3925969B1 (en) 2025-09-03
JP6810146B2 (ja) 2021-01-06
BR112018010535A2 (pt) 2018-11-13
CA3071494C (en) 2021-12-14
CN116478245A (zh) 2023-07-25
CN108473541A (zh) 2018-08-31
CA3071494A1 (en) 2017-06-01
US11034727B2 (en) 2021-06-15
US20240199695A1 (en) 2024-06-20
CA3006313C (en) 2020-02-11
DK3380495T3 (da) 2021-08-16
AU2021201085B2 (en) 2023-01-19
US20250296957A1 (en) 2025-09-25
PL3380495T3 (pl) 2021-12-13
EP3925969A1 (en) 2021-12-22
AU2016358324A1 (en) 2018-07-05
US11780882B2 (en) 2023-10-10
JP7095035B2 (ja) 2022-07-04
US20220356209A1 (en) 2022-11-10
AU2021201085A1 (en) 2021-03-11
WO2017088058A1 (en) 2017-06-01
ZA201804117B (en) 2022-08-31

Similar Documents

Publication Publication Date Title
AU2021201085B2 (en) Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
EP3138568B1 (en) New stable antibody-drug conjugate, preparation method therefor, and use thereof
US20220000971A1 (en) Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry
US20200157151A1 (en) Peptide compounds, conjugate compounds and uses thereof for treating inflammatory diseases
WO2016108587A1 (ko) 리피바디 유도체-약물 복합체, 그 제조방법 및 용도
HK40066016B (en) Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
HK40066016A (en) Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
EP4201431A1 (en) Intermediate for preparing antibody-drug conjugate (adc), preparation method therefor, and use thereof
BR112018010535B1 (pt) Compostos peptídicos e conjugados peptídicos para o tratamento de câncer por quimioterapia com mediação por um receptor
HK1259948B (en) Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
HK1259948A1 (en) Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
CZ200132A3 (cs) Podávači systém

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)